Science Finances the Development of an Infrastructure for Advanced Therapies in Spain with €45

Driving advanced therapy. The Carlos III Health Institute (IscIII), as an organism dependent on the Ministry of Science, Innovation and Universities,  has announced the allocation of €45 million for the State Network Consortium for the Development of Advanced Therapies Medicines (Certera).

This initiative, integrated into the Strategic Plan for Economic Recovery (Perte) for Vanguard Health and financed through the Recovery, Resilience and Transformation Mechanism, will benefit 43 entities distributed in 14 autonomous communities of Spain.

Certera focuses on promoting the development of innovative medicines and therapeutic solutions through the use of gene therapy, cell therapy and tissue engineering to combat different diseases. 

The grants will support the development of this network and  promote facilities, infrastructure, skills and human resources, distributed across three technical levels:  production of advanced therapy medicines, expansion of production capacity and provision of services for the development of advanced therapy medicines.

The consortium  seeks to link academic and technological capabilities from the research phase to early clinical trials , with the purpose of amplifying the potential already present or under construction in the field of advanced therapies in Spain.

Read more about the Ministry of Science and the allocation of 45 million to innovation in health, and find the most important financial news of the day with the Born2Invest mobile app.

The initiative of the Ministry of Science will benefit 43 entities distributed in 14 autonomous communities of Spain

The distribution of the selected entities shows a significant presence in regions such as Catalonia, Madrid, Andalusia, the Basque Country and other communities, reflecting the interest and collaboration in this project at the national level. The financing assigned to each entity will depend on its participation and contribution  to the different levels of production and services defined in the call.

The Minister of Science, Innovation and Universities, Diana Morant, highlighted the Government’s commitment to investing in the  development of innovative medicines, ensuring access to advanced therapies through the National Health System . For his part, Cristóbal Belda, director of the ISCIII, highlighted the challenge of selecting projects with potential future value, emphasizing the importance of academic hospital environments in the creation of these therapies.

With this financing, significant progress is expected in promoting advanced treatments in Spain, contributing to a faster and more efficient development of innovative therapeutic treatments for the benefit of public health.

__

(Featured image by ernestoeslava via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.